About Rs 300 crore would be invested for biologics manufacturing facilities by Aurobindo Pharma's unit
The company Auro Vaccines is in the business of creating and producing biological vaccines.
admin
On Thursday, Aurobindo Pharma announced intentions to invest up to Rs 300 crore in the capacity development of biologics manufacturing facilities through its wholly owned subsidiary, CuraTeQ Biologics.
Aurobindo Pharma stated in a regulatory filing that the board of directors of CuraTeQ Biologics Pvt Ltd approved the expansion of its operations by creating a second, larger-capacity mammalian cell culture manufacturing facility to fulfil future demand at its meeting on Thursday.
The plant is expected to be completely operational by FY26, it added, adding that the capital cost for ramping up capabilities is estimated to be around Rs 300 crore. In order to use capacity effectively, the board also approved starting contract manufacturing operations (CMO) for biologicals.
As the market for global biologics contract manufacturing is increasing at a rate of 8–10%, this would improve business possibilities in the field, and CuraTeQ said it will actively seek out customers in the CMO sector.
The firm also announced that Auro Vaccines Pvt Ltd's board had approved studying the possibility of providing contract manufacturing services to international vaccine developers in order to efficiently utilise its current manufacturing capacity.
The company Auro Vaccines is in the business of creating and producing biological vaccines.
